Marinus Pharmaceuticals, Inc.

Informe acción NasdaqGM:MRNS

Capitalización de mercado: US$30.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Marinus Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Marinus Pharmaceuticals de 66.2% y 26.3% respectivamente, mientras que el BPA crecerá en un 71.3% al año.

Información clave

66.2%

Tasa de crecimiento de los beneficios

71.34%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals14.4%
Tasa de crecimiento de los ingresos26.3%
Rentabilidad financiera futuran/a
Cobertura de analistas

Good

Última actualización03 Jan 2025

Actualizaciones recientes sobre el crecimiento futuro

Artículo de análisis • Aug 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest quarterly results, disappointing...
Artículo de análisis • May 11

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) just released its latest first-quarter report and things are not looking...

Recent updates

Artículo de análisis • Sep 20

A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

It's not a stretch to say that Marinus Pharmaceuticals, Inc.'s ( NASDAQ:MRNS ) price-to-sales (or "P/S") ratio of 2.9x...
Artículo de análisis • Aug 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest quarterly results, disappointing...
Artículo de análisis • May 11

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) just released its latest first-quarter report and things are not looking...
Artículo de análisis • Apr 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

The Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) share price has fared very poorly over the last month, falling by a...
Artículo de análisis • Mar 08

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest annual results, disappointing...
Artículo de análisis • Dec 22

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Artículo de análisis • Sep 22

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Artículo de análisis • Jun 12

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...
Artículo de análisis • May 16

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

Shareholders in Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) may be thrilled to learn that the analysts have just...
Artículo de análisis • Oct 26

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

One thing we could say about the analysts on Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) - they aren't optimistic...
Artículo de análisis • Oct 12

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Sep 22

Marinus Pharmaceuticals: Positive News Flow Of Note

Summary Today, we put Marinus Pharmaceuticals back in the spotlight as the stock has held up well even as the market has sold off. The company also has seen some positive news flow of late including the sale of a priority review voucher and some additional cash flow from BARDA. An investment analysis follows in the paragraphs below. Humility means accepting reality with no attempt to outsmart it.”― David Richo When we last revisited Marinus Pharmaceuticals, Inc. (MRNS) in May, we recommended it for a small covered call position. That seems to have been a prudent call to this point as the stock is basically trading flat/slightly up to when we last looked at it. Given how poorly biotech stocks have traded in 2022, that marks a victory. Seeking Alpha We are circling back today to update the investment thesis around Marinus as the company has seen some positive news flow in recent weeks. An analysis follows below. Company Overview: Marinus Pharmaceuticals is focused on the development of therapies for the treatment of rare genetic epilepsies and other seizure disorders. The company is based outside of Philadelphia, PA. The stock trades for around $6.50 a share and sports an approximate market capitalization of $260 million. May Company Presentation The company has one primary asset under development for multiple indications called ganaxolone. This compound is also known by its brand name Ztalmy was approved this March for seizures associated with cyclin-dependent-kinase like 5 (CDKL5) deficiency disorder (CDD). The marketing application for Ztalmy in Europe is currently undergoing review by the European Medicines Agency or EMA. The company plans to submit complete responses to questions from the EMA in November and they should render a decision in the first quarter of next year. May Company Presentation Recent Developments for Marinus: The priority review voucher Marinus garnered via the approval of Ztalmy by the FDA was sold at the end of August for $110 million. This bolstered the company's cash reserves substantially and was right in the range ($100 million to $125 million) these vouchers have received in recent years. In addition, it was announced that Biomedical Advanced Research and Development Authority or BARDA had exercised its first contract option worth ~$12.3M, to support U.S. onshoring of manufacturing capabilities of Ztalmy. That still leaves some $39 million of potential awards under this contract, $21 million in previously approved base-period funding and up to $18 million across two additional option periods. Company Website The company continues to advance ganaxolone against other indications. Marinus has a Phase 3 trial "RAISE" to evaluate ganaxolone to treat Refractory Status Epilepticus or RSE. Topline results from this study should be out in the second half of 2023. This study is being funded by BARDA. May Company Presentation Recently the first patient was randomized and dosed in a Phase 3 trial to evaluate ganaxolone to treat Tuberous Sclerosis Complex or TSC. The study will consist of approximately targeting 80 clinical sites and topline results are not expected until the first quarter of 2024 at the earliest. May Company Presentation Results from a Phase 2 study around RSE was published in June and a Phase 3 study for RSE 'RAISE II' (for European registration) is expected to begin enrollment in the second half of 2023. May Company Presentation A Phase 2 trial 'RESET' evaluating ganaxolone in established status epilepticus on track to begin U.S. enrollment in the second half of this year. A Phase 2 trial to evaluate ganaloxone to treat Lennox-Gastaut syndrome is now targeted to begin in 2023. Analyst Commentary & Balance Sheet: The analyst community also seems to be turning more sanguine on Marinus' story. Over the past five weeks, four analyst firms including Robert W. Baird and JMP Securities have reissued Buy ratings on MRNS. Price targets proffered range from $17 to $32 a share. Approximately five percent of the outstanding float is currently held short. There has been no insider activity in this equity since March of 2021. The company ended the second quarter of this year with just over $90 million in cash and marketable securities on its balance sheet after posting a net loss of $39.4 million in the quarter. With the receipts from the priority review voucher in hand, management believes current funding levels are sufficient to fund it into the fourth quarter of 2023. Marinus has approximately $70 million of long term debt. Verdict: There are a wide range of sales and earnings estimates from the analyst community at the present time. Right now they expect the company to lose just over two bucks a share in FY2022 and over $3.50 a share in FY2023 as the company spends big on the rollout of Ztalmy and advancing its pipeline. Revenue estimates range from approximately $15 million to $60 million next fiscal year. The company had just $1.8 million worth of revenue in the second quarter.
Seeking Alpha • Aug 29

Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M

Marinus Pharmaceuticals (NASDAQ:MRNS) on Monday said it had closed on the sale of a U.S. FDA voucher for $110M. The voucher, called the Rare Pediatric Disease Priority Review Voucher, entitles MRNS to a priority review from the agency and proceeds to carry out its drug development activities with an aim to treat rare pediatric diseases. MRNS said it had received the $110M of gross funds, which are in addition to the $92.3M the had reported in cash and cash equivalents as of June 30. The company said it would use the proceeds from the closing of the sale on the voucher for the commercial launch of seizure treatment Ztalmy, execution of its phase 3 clinical programs and other general expenditures. With the addition of this funding, MRNS said it now expects to fund its expenses and requirements and maintain the minimum cash balance required under its debt facility into Q4 2023. MRNS stock +4.2% to $6.97 after hours.
Artículo de análisis • Aug 13

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Aug 10

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Marinus Pharmaceuticals (NASDAQ:MRNS) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.93 (-43.1% Y/Y) and the consensus Revenue Estimate is $2.31M (+20.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Seeking Alpha • Jul 28

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Marinus Pharmaceuticals (NASDAQ:MRNS) on Thursday announced the U.S. commercial launch of Ztalmy for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older. CDD is a genetic disorder caused due to mutations in the CDKL5 gene. It is characterized by seizures, developmental delay and intellectual disability. Ztalmy, which is an oral treatment, got U.S. FDA approval earlier this year in March. Marinus (MRNS) also said it had established a patient support program called Ztalmy One which facilitates access to the treatment, including prescription benefits and financial support for patients with no insurance.
Seeking Alpha • May 05

Revisiting Marinus Pharmaceuticals

Today, we put biopharma concern Marinus Pharmaceuticals back in the spotlight for the first time in more than a year. Despite the fall in the stock recently, analyst firms remain strongly positive on the shares. An updated investment analysis follows in the paragraphs below.

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:MRNS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2027968N/AN/A5
12/31/202674-18N/AN/A5
12/31/202554-40777
12/31/202435-118-101-1006
9/30/202431-140-116-115N/A
6/30/202430-149-121-120N/A
3/31/202428-145-114-114N/A
12/31/202331-141-118-118N/A
9/30/202331-134-113-113N/A
6/30/202326-29-119-117N/A
3/31/202322-35-128-127N/A
12/31/202225-20-115-113N/A
9/30/202220-14-115-113N/A
6/30/202228-105-80-78N/A
3/31/202228-91-69-67N/A
12/31/202115-99-58-55N/A
9/30/202115-88-52-50N/A
6/30/20215-84-71-70N/A
3/31/20214-76-63-63N/A
12/31/20202-76-61-61N/A
9/30/20200-74-61-61N/A
6/30/2020N/A-72-58-58N/A
3/31/2020N/A-69-51-51N/A
12/31/2019N/A-54-49-49N/A
9/30/2019N/A-49-42-42N/A
6/30/2019N/A-46-37-36N/A
3/31/2019N/A-43-34-33N/A
12/31/2018N/A-37-28-28N/A
9/30/2018N/A-31-23-23N/A
6/30/2018N/A-24N/A-19N/A
3/31/2018N/A-19N/A-18N/A
12/31/2017N/A-19N/A-19N/A
9/30/2017N/A-20N/A-20N/A
6/30/2017N/A-22N/A-24N/A
3/31/2017N/A-27N/A-26N/A
12/31/2016N/A-29N/A-25N/A
9/30/2016N/A-30N/A-24N/A
6/30/2016N/A-29N/A-23N/A
3/31/2016N/A-25N/A-22N/A
12/31/2015N/A-25N/A-20N/A
9/30/2015N/A-21N/A-17N/A
6/30/2015N/A-18N/A-14N/A
3/31/2015N/A-17N/A-11N/A
12/31/2014N/A-13N/A-9N/A
9/30/2014N/A-12N/A-10N/A
6/30/2014N/A-12N/A-8N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MRNS sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que MRNS sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que MRNS sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (26.3% al año) de MRNS crezcan más rápidamente que los del mercado US (11.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (26.3% al año) de MRNS crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MRNS se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2025/02/10 16:36
Precio de las acciones al final del día2025/02/07 00:00
Beneficios2024/09/30
Ingresos anuales2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Marinus Pharmaceuticals, Inc. está cubierta por 7 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Kimberly LeeBrean Capital Historical (Janney Montgomery)
François BriseboisCraig-Hallum Capital Group LLC
Douglas TsaoH.C. Wainwright & Co.